Riskpilot← Back to searchSign inGet full accessSTL BIO AB
ABActiveOrg 5594170887Årgångsgatan 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20230 employees
Revenue 2024
SEK 521K
-17% vs 2023
EBITDA margin
85.6%
-17% vs 2023
Equity ratio
84.7%
Financial strength
Net profit 2024
SEK 364K
-15% vs 2023
| Revenue | SEK 521K | -17% |
| EBITDA | SEK 446K | -17% |
| Net profit | SEK 364K | -15% |
| Total assets | SEK 724K | +30% |
| Equity | SEK 613K | +35% |
| Employees | 0 | — |
Legal name
STL BIO AB
Org number
5594170887
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 januari 2023
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva konsultverksamhet inom naturvetenskaplig och teknisk forskning och utveckling samt annan allmän öppen hälso- och sjukvård. Bolaget skall även bedriva konsultverksamhet inom management och ledarskap och därmed förenlig verksamhet.
Address
Årgångsgatan 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 630 | 521 |
| Staff expenses | — | — |
| EBITDA | 540 | 446 |
| Depreciation & amort. | −0 | −0 |
| EBIT | 540 | 446 |
| Net financials | — | 14 |
| Profit before tax | 540 | 460 |
| Tax | −112 | −96 |
| Net profit | 428 | 364 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 558 | 724 |
| Equity | 453 | 613 |
| Long-term debt | 0 | 0 |
| Short-term debt | 105 | 111 |
| Total debt | 105 | 111 |
EBITDA margin
85.6%
This company
15.8%
Market median
+442% vs market
20232024
Equity ratio
84.7%
This company
38.2%
Market median
+122% vs market
20232024
Return on equity
59.4%
This company
18.4%
Market median
+223% vs market
20232024
Net profit margin
69.9%
This company
8.1%
Market median
+763% vs market
20232024
Asset turnover
0.72×
This company
1.12×
Market median
-36% vs market
20232024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20232024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ST Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of STL BIO AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stig Tryggve Linder | Chief Executive Officer | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Ulla Margareta Sten Linder | Chairman | 0 companies |
| David Bo Rikard Linder | Deputy Board Member | 0 companies |
| Louise Maria Margareta Kampen | Deputy Board Member | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |